Literature DB >> 16681772

p53, epidermal growth factor, and platelet-derived growth factor in uterine leiomyosarcoma and leiomyomas.

S E Anderson1, D Nonaka, S Chuai, A B Olshen, D Chi, P Sabbatini, R A Soslow.   

Abstract

Uterine leiomyosarcoma (ULMS) is an aggressive gynecological disease. Although ULMS are often found in association with benign leiomyoma (LMA), little is known regarding the relationship between these benign and malignant smooth muscle neoplasms. The objective of this study was to evaluate the expression of epidermal growth factor (EGFR), platelet-derived growth factor (PDGFR), and p53 in ULMS specimens, their prognostic relevance, and the expression of these molecular markers when compared to benign LMA specimens. Between 1991 and 2001, 25 patients were identified with high-grade primary ULMS and for whom tissue was available. Tissue microarray was created with three representative cores from each of the ULMS cases as well as from 19 patients with benign uterine leiomyomata. Immunohistochemical (IHC) staining was performed for EGFR, PDGFR, and p53. Negative and positive IHC staining was scored for each marker. Outcome analysis was performed only for ULMS. Survival was determined from the time of initial diagnosis to last follow-up. Twelve (48%) ULMS expressed p53 compared to none of the LMA (P < 0.001), and 15 (60%) ULMS cases showed PDGFR expression compared to 32% of LMA samples (P= 0.08). EGFR expression did not differ between ULMS and LMA groups. ULMS patients with p53 expression had a poorer survival compared to ULMS patients with negative expression (P= 0.07). ULMS tumor stage had the strongest association with overall survival (P= 0.05). Our study supports previous investigations indicating that p53 expression may serve as a prognostic marker for ULMS patients. The difference in PDGFR expression between ULMS and LMA demonstrated a trend toward significance. EGFR was not commonly expressed in ULMS. These uniquely expressed markers may assist in stratifying patients by survival and identify novel therapeutic markers. Clearly, further investigation is needed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16681772     DOI: 10.1111/j.1525-1438.2006.00542.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  8 in total

1.  BCOR is a robust diagnostic immunohistochemical marker of genetically diverse high-grade endometrial stromal sarcoma, including tumors exhibiting variant morphology.

Authors:  Sarah Chiang; Cheng-Han Lee; Colin J R Stewart; Esther Oliva; Lien N Hoang; Rola H Ali; Martee L Hensley; Javier A Arias-Stella; Denise Frosina; Achim A Jungbluth; Ryma Benayed; Marc Ladanyi; Meera Hameed; Lu Wang; Yu-Chien Kao; Cristina R Antonescu; Robert A Soslow
Journal:  Mod Pathol       Date:  2017-06-16       Impact factor: 7.842

Review 2.  Practical issues in uterine pathology from banal to bewildering: the remarkable spectrum of smooth muscle neoplasia.

Authors:  Esther Oliva
Journal:  Mod Pathol       Date:  2016-01       Impact factor: 7.842

3.  Immunohistochemical studies on uterine carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma: expression and prognostic importance of ten different markers.

Authors:  Riitta Koivisto-Korander; Ralf Butzow; Anna-Maija Koivisto; Arto Leminen
Journal:  Tumour Biol       Date:  2010-12-16

4.  A role for BRCA1 in uterine leiomyosarcoma.

Authors:  Deyin Xing; George Scangas; Mai Nitta; Lei He; Xuan Xu; Yevgeniya J M Ioffe; Paul-Joseph Aspuria; Cyrus Y Hedvat; Matthew L Anderson; Esther Oliva; Beth Y Karlan; Gayatry Mohapatra; Sandra Orsulic
Journal:  Cancer Res       Date:  2009-10-20       Impact factor: 12.701

Review 5.  Current Chemotherapy and Potential New Targets in Uterine Leiomyosarcoma.

Authors:  Shabnam Momtahen; John Curtin; Khush Mittal
Journal:  J Clin Med Res       Date:  2016-01-26

Review 6.  Uterine sarcoma - current perspectives.

Authors:  Charlotte Benson; Aisha B Miah
Journal:  Int J Womens Health       Date:  2017-08-31

7.  Molecular mechanisms of uterine leiomyosarcomas: involvement of defect in LMP2 expression.

Authors:  Takuma Hayashi; Yuto Shimamura; Taro Saegusa; Akiko Horiuchi; Yukihiro Kobayashi; Nobuyoshi Hiraoka; Yae Kanai; Hiroyuki Aburatani; Kenji Sano; Ikuo Konishi
Journal:  Gene Regul Syst Bio       Date:  2008-07-22

Review 8.  Potential Therapeutic Targets in Uterine Sarcomas.

Authors:  Tine Cuppens; Sandra Tuyaerts; Frédéric Amant
Journal:  Sarcoma       Date:  2015-10-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.